İlaçlar ve Kronobiyoloji
Özet
Kronobiyoloji ve ilaç uygulamaları arasındaki ilişkiyi inceleyen bu metin, organizmanın 24 saatlik sirkadiyen ritminin ilaçların farmakokinetik (FK) ve farmakodinamik (FD) süreçleri üzerindeki kritik etkilerini ele almaktadır. Kronofarmakoloji bilimi, ilaçların emilim (absorbsiyon), dağılım, metabolizma ve atılım (ADME) aşamalarının gün içindeki fizyolojik dalgalanmalardan etkilendiğini ve bu durumun kronofarmakokinetik parametreleri doğrudan değiştirdiğini göstermektedir. Gastrointestinal kan akımı, pH ve gastrik boşalma sürelerindeki sirkadiyen değişimler sabah ve akşam uygulamalarında ilaç emilimini farklılaştırırken, plazma proteinlerine bağlanma oranlarındaki ritmik varyasyonlar da ilaçların dokulardaki dağılım hacmini etkilemektedir. Karaciğerdeki Faz I, II ve III metabolizma süreçleri ile böbreklerdeki glomerüler filtrasyon hızı ve tübüler sekresyon basamakları, biyolojik saat genleri ve PAR bZip transkripsiyon faktörleri tarafından moleküler düzeyde regüle edilmektedir. Hücresel hassasiyeti ifade eden kronestezi ise reseptör ve sinyal yolaklarındaki ritmisite nedeniyle benzer plazma konsantrasyonlarında bile farklı tedavi yanıtları doğurmaktadır. Sonuç olarak, hastalıkların semptom zamanlaması ile ilaçların etkinlik ve toksisite profillerinin günün saatlerine göre optimize edilmesi esasına dayanan kronoterapi yaklaşımları, maksimum terapötik başarı ve minimum yan etki için rasyonel farmakoterapinin geleceğini şekillendirmektedir.
This text, which examines the relationship between chronobiology and drug applications, addresses the critical effects of the organism's 24-hour circadian rhythm on the pharmacokinetic (PK) and pharmacodynamic (PD) processes of drugs. The science of chronopharmacology demonstrates that the absorption, distribution, metabolism, and excretion (ADME) phases of drugs are influenced by diurnal physiological fluctuations, directly altering chronopharmacokinetic parameters. Circadian variations in gastrointestinal blood flow, pH, and gastric emptying times differentiate drug absorption between morning and evening administrations, while rhythmic variations in plasma protein binding rates affect the volume of drug distribution in tissues. Phase I, II, and III metabolism processes in the liver, along with glomerular filtration rate and tubular secretion steps in the kidneys, are regulated at the molecular level by biological clock genes and PAR bZip transcription factors. Chronesthesy, which refers to cellular sensitivity, produces distinct therapeutic responses even at similar plasma concentrations due to rhythmicity in receptors and signaling pathways. Consequently, chronotherapy approaches, based on optimizing the timing of disease symptoms and the efficacy and toxicity profiles of drugs according to the time of day, shape the future of rational pharmacotherapy for maximum therapeutic success and minimum side effects.
Referanslar
Smolensky MH, Peppas NA. Chronobiology, drug delivery, and chronotherapeutics. Adv Drug Deliv Rev. 2007;59(9-10):828-51.
Schulz P, Steimer T. Neurobiology of circadian systems. CNS Drugs. 2009;23 Suppl 2:3-13.
Dallmann R, Brown SA, Gachon F. Chronopharmacology: new insights and therapeutic implications. Annual review of pharmacology and toxicology. 2014;54:339-61.
Gachon F, Nagoshi E, Brown SA, et al. The mammalian circadian timing system: from gene expression to physiology. Chromosoma. 2004;113(3):103-12.
Green CB, Takahashi JS, Bass J. The meter of metabolism. Cell. 2008;134(5):728-42.
Kovac J, Husse J, Oster H. A time to fast, a time to feast: the crosstalk between metabolism and the circadian clock. Mol Cells. 2009;28(2):75-80.
Ozturk N, Ozturk D, Kavakli IH, et al. Molecular aspects of circadian pharmacology and relevance for cancer chronotherapy. International journal of molecular sciences. 2017;18(10):2168.
Tahara Y, Shibata S. Chrono-biology, chrono-pharmacology, and chrono-nutrition. Journal of pharmacological sciences. 2014;124(3):320-35.
Lemmer B. Chronopharmacology and controlled drug release. Expert opinion on drug delivery. 2005;2(4):667-81.
Bruguerolle B. Chronopharmacokinetics. Clinical pharmacokinetics. 1998;35(2):83-94.
Lemmer B. Discoveries of rhythms in human biological functions: a historical review. Chronobiology international. 2009;26(6):1019-68.
Bruguerolle B, editor General concepts and new trends in chronopharmacology. Biologic clocks: Mechanisms and applications, Proceedings of the International Congress on Chronobiology Amsterdam: Elsevier; 1998.
Lemmer B, editor Chronopharmacology: time, a key in drug treatment. Annales de biologie clinique; 1994: Paris, Expansion scientifique francaise.
Chassard D, Bruguerolle B. Chronobiology and anesthesia. Anesthesiology-Philadelphia Then Hagerstown. 2004;100(2):413-27.
Gaspar LS, Álvaro AR, Carmo‐Silva S, et al. The importance of determining circadian parameters in pharmacological studies. British Journal of Pharmacology. 2019;176(16):2827-47.
Dallmann R, Okyar A, Lévi F. Dosing-time makes the poison: circadian regulation and pharmacotherapy. Trends in molecular medicine. 2016;22(5):430-45.
Levi F, Schibler U. Circadian rhythms: mechanisms and therapeutic implications. Annu Rev Pharmacol Toxicol. 2007;47:593-628.
Ballesta A, Innominato PF, Dallmann R, et al. Systems Chronotherapeutics. Pharmacol Rev. 2017;69(2):161-99.
Gachon F, Olela FF, Schaad O, et al. The circadian PAR-domain basic leucine zipper transcription factors DBP, TEF, and HLF modulate basal and inducible xenobiotic detoxification. Cell metabolism. 2006;4(1):25-36.
Musiek ES, FitzGerald GA. Molecular clocks in pharmacology. Circadian clocks. 2013:243-60.
Baraldo M. The influence of circadian rhythms on the kinetics of drugs in humans. Expert opinion on drug metabolism & toxicology. 2008;4(2):175-92.
Zhang R, Lahens NF, Ballance HI, et al. A circadian gene expression atlas in mammals: implications for biology and medicine. Proceedings of the National Academy of Sciences. 2014;111(45):16219-24.
Lévi F, Okyar A. Circadian clocks and drug delivery systems: impact and opportunities in chronotherapeutics. Taylor & Francis; 2011. p. 1535-41.
Reinberg A, Smolensky M. Circadian changes of drug disposition in man. Clinical pharmacokinetics. 1982;7(5):401-20.
Erkekoglu P, Baydar T. Chronopharmacokinetics of drugs in toxicological aspects: a short review for pharmacy practitioners. Journal of research in pharmacy practice. 2012;1(1):3.
Cederroth CR, Albrecht U, Bass J, et al. Medicine in the fourth dimension. Cell metabolism. 2019;30(2):238-50.
Ohdo S. Chrono-Drug Discovery and Development Based on Circadian Rhythm of Molecular, Cellular and Organ Level. Biol Pharm Bull. 2021;44(6):747-61.
Bruguerolle B, Boulamery A, Simon N. Biological rhythms: a neglected factor of variability in pharmacokinetic studies. Journal of pharmaceutical sciences. 2008;97(3):1099-108.
Okyar A, Dressler C, Hanafy A, et al. Circadian variations in exsorptive transport: in situ intestinal perfusion data and in vivo relevance. Chronobiology international. 2012;29(4):443-53.
Ben-Cherif W, Dridi I, Aouam K, et al. Circadian variation of valproic acid pharmacokinetics in mice. European Journal of Pharmaceutical Sciences. 2013;49(4):468-73.
Bicker J, Alves G, Falcão A, et al. Timing in drug absorption and disposition: The past, present, and future of chronopharmacokinetics. British journal of pharmacology. 2020;177(10):2215-39.
Ayyar VS, Sukumaran S. Circadian rhythms: influence on physiology, pharmacology, and therapeutic interventions. J Pharmacokinet Pharmacodyn. 2021;48(3):321-38.
Dong D, Yang D, Lin L, et al. Circadian rhythm in pharmacokinetics and its relevance to chronotherapy. Biochem Pharmacol. 2020;178:114045.
Nakano S, Hollister LE. Chronopharmacology of amitriptyline. Clinical Pharmacology & Therapeutics. 1983;33(4):453-9.
Nakano S, Watanabe H, Nagai K, et al. Circadian stage‐dependent changes in diazepam kinetics. Clinical Pharmacology & Therapeutics. 1984;36(2):271-7.
Kamali F, Fry J, Bell G. Temporal variations in paracetamol absorption and metabolism in man. Xenobiotica. 1987;17(5):635-41.
Müller F, Van Dyk M, Hundt H, et al. Pharmacokinetics of temazepam after day-time and night-time oral administration. European journal of clinical pharmacology. 1987;33(2):211-4.
Lemmer B, Nold G. Circadian changes in estimated hepatic blood flow in healthy subjects. British journal of clinical pharmacology. 1991;32(5):627-9.
Lemmer B, Nold G, Behne S, et al. Chronopharmacokinetics and cardiovascular effects of nifedipine. Chronobiology international. 1991;8(6):485-94.
Scheidel B, Lemmer B. Chronopharmacology of oral nitrates in healthy subjects. Chronobiology international. 1991;8(5):409-19.
Bardal SK, Waechter JE, Martin DS. Applied pharmacology: Elsevier Health Sciences; 2011.
Gries JM, Benowitz N, Verotta D. Chronopharmacokinetics of nicotine. Clinical Pharmacology & Therapeutics. 1996;60(4):385-95.
Harris BE, Song R, Soong S-j, et al. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer research. 1990;50(1):197-201.
Harris BE, Song R, Soong S-j, et al. Circadian variation of 5-fluorouracil catabolism in isolated perfused rat liver. Cancer research. 1989;49(23):6610-4.
Ballesta A, Dulong S, Abbara C, et al. A combined experimental and mathematical approach for molecular-based optimization of irinotecan circadian delivery. PLoS computational biology. 2011;7(9):e1002143.
Lévi F, Okyar A, Dulong S, et al. Circadian timing in cancer treatments. Annual review of pharmacology and toxicology. 2010;50:377-421.
Li X-M, Metzger G, Filipski E, et al. Pharmacologic modulation of reduced glutathione circadian rhythms with buthionine sulfoximine: relationship with cisplatin toxicity in mice. Toxicology and applied pharmacology. 1997;143(2):281-90.
Hediger MA, Clémençon B, Burrier RE, et al. The ABCs of membrane transporters in health and disease (SLC series): introduction. Molecular aspects of medicine. 2013;34(2-3):95-107.
Okamura A, Koyanagi S, Dilxiat A, et al. Bile acid-regulated peroxisome proliferator-activated receptor-α (PPARα) activity underlies circadian expression of intestinal peptide absorption transporter PepT1/Slc15a1. Journal of Biological Chemistry. 2014;289(36):25296-305.
Matsunaga N, Ikeda M, Takiguchi T, et al. The molecular mechanism regulating 24‐hour rhythm of CYP2E1 expression in the mouse liver. Hepatology. 2008;48(1):240-51.
Takiguchi T, Tomita M, Matsunaga N, et al. Molecular basis for rhythmic expression of CYP3A4 in serum-shocked HepG2 cells. Pharmacogenetics and genomics. 2007;17(12):1047-56.
Matsunaga N, Inoue M, Kusunose N, et al. Time-dependent interaction between differentiated embryo chondrocyte-2 and CCAAT/enhancer-binding protein α underlies the circadian expression of CYP2D6 in serum-shocked HepG2 cells. Molecular pharmacology. 2012;81(5):739-47.
Kanemitsu T, Tsurudome Y, Kusunose N, et al. Periodic variation in bile acids controls circadian changes in uric acid via regulation of xanthine oxidase by the orphan nuclear receptor PPARα. Journal of Biological Chemistry. 2017;292(52):21397-406.
Cao QR, Kim TW, Choi JS, et al. Circadian variations in the pharmacokinetics, tissue distribution and urinary excretion of nifedipine after a single oral administration to rats. Biopharmaceutics & drug disposition. 2005;26(9):427-37.
Koopman M, Koomen G, Krediet R, et al. Circadian rhythm of glomerular filtration rate in normal individuals. Clinical science (London, England: 1979). 1989;77(1):105-11.
Sukumaran S, Almon RR, DuBois DC, et al. Circadian rhythms in gene expression: Relationship to physiology, disease, drug disposition and drug action. Advanced drug delivery reviews. 2010;62(9-10):904-17.
Stow LR, Gumz ML. The circadian clock in the kidney. Journal of the American Society of Nephrology. 2011;22(4):598-604.
Zuber AM, Centeno G, Pradervand S, et al. Molecular clock is involved in predictive circadian adjustment of renal function. Proceedings of the National Academy of Sciences. 2009;106(38):16523-8.
Mesnard-Ricci B, White CA. Chronokinetics of active biliary ampicillin secretion in rats. Chronobiology international. 1998;15(4):309-21.
Nikolaeva S, Ansermet C, Centeno G, et al. Nephron-specific deletion of circadian clock gene Bmal1 alters the plasma and renal metabolome and impairs drug disposition. Journal of the American Society of Nephrology. 2016;27(10):2997-3004.
Takane H, Ohdo S, Yamada T, et al. Chronopharmacology of antitumor effect induced by interferon-β in tumor-bearing mice. Journal of Pharmacology and Experimental Therapeutics. 2000;294(2):746-52.
Mager DE, Neuteboom B, Efthymiopoulos C, et al. Receptor-mediated pharmacokinetics and pharmacodynamics of interferon-β1a in monkeys. Journal of Pharmacology and Experimental Therapeutics. 2003;306(1):262-70.
Koyanagi S, Kuramoto Y, Nakagawa H, et al. A molecular mechanism regulating circadian expression of vascular endothelial growth factor in tumor cells. Cancer research. 2003;63(21):7277-83.
Lauriola M, Enuka Y, Zeisel A, et al. Diurnal suppression of EGFR signalling by glucocorticoids and implications for tumour progression and treatment. Nature Communications. 2014;5(1):1-13.
Nakagawa H, Takiguchi T, Nakamura M, et al. Basis for dosing time-dependent change in the anti-tumor effect of imatinib in mice. Biochemical pharmacology. 2006;72(10):1237-45.
Kusunose N, Koyanagi S, Hamamura K, et al. Molecular basis for the dosing time-dependency of anti-allodynic effects of gabapentin in a mouse model of neuropathic pain. Molecular pain. 2010;6:1744-8069-6-83.
Fujiwara Y, Ando H, Ushijima K, et al. Dosing-time-dependent effect of rivaroxaban on coagulation activity in rats. Journal of Pharmacological Sciences. 2017;134(4):234-8.
Brunner‐Ziegler S, Jilma B, Schörgenhofer C, et al. Comparison between the impact of morning and evening doses of rivaroxaban on the circadian endogenous coagulation rhythm in healthy subjects. Journal of Thrombosis and Haemostasis. 2016;14(2):316-23.
Koyanagi S. Chrono-Pharmaceutical Approaches to Optimize Dosing Regimens Based on the Circadian Clock Machinery. Biol Pharm Bull. 2021;44(11):1577-84.
